Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS‐mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug resistance. We show that BET proteins are overexpresse...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:EMBO Mol Med
Auteurs principaux: Echevarría‐Vargas, Ileabett M, Reyes‐Uribe, Patricia I, Guterres, Adam N, Yin, Xiangfan, Kossenkov, Andrew V, Liu, Qin, Zhang, Gao, Krepler, Clemens, Cheng, Chaoran, Wei, Zhi, Somasundaram, Rajasekharan, Karakousis, Giorgos, Xu, Wei, Morrissette, Jennifer JD, Lu, Yiling, Mills, Gordon B, Sullivan, Ryan J, Benchun, Miao, Frederick, Dennie T, Boland, Genevieve, Flaherty, Keith T, Weeraratna, Ashani T, Herlyn, Meenhard, Amaravadi, Ravi, Schuchter, Lynn M, Burd, Christin E, Aplin, Andrew E, Xu, Xiaowei, Villanueva, Jessie
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2018
Sujets:
Research Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5938620/
https://ncbi.nlm.nih.gov/pubmed/29650805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201708446
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires